First Trials Of Cannabis Treatment For Dementia Begin in Australia

Researchers at the University of Notre Dame in Western Australia want to transform the way we treat dementia and other cognitive impairments associated with old age. And they hope their upcoming study will point the way. In partnership with MGC Pharmaceuticals, the University of Notre Dame’s Institute for Health Research is conducting the first-ever clinical trials to study cannabis as a treatment for dementia and Alzheimer’s symptoms in humans. Over 14 months, researchers will conduct a series of 16-week trials involving a total of 50 participants, all aged 65 and older. The actual clinical trials are currently slated to begin in early 2020, and Phase II is currently underway to recruit eligible participants.

Trailblazing Study Investigates Cannabis as Dementia and Alzheimer’s Treatment

Studies on cannabis that actually involve humans are very few and far between. But late this August, the University of Notre Dame in Western Australia’s (UNDA) Human Research Ethics Committee (HREC) gave the green light to Institute for Health Research scientists to carry out the first clinical trials to study cannabis as a treatment for mild dementia and Alzheimer’s disease. The HREC approval followed the completion of an ethical review, required under Australia’s National Statement on Ethical Conduct

Read More Here…

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Bud Digest

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top